Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine
Language English Country United States Media print
Document type Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adalimumab therapeutic use MeSH
- Anti-Inflammatory Agents therapeutic use MeSH
- Azathioprine therapeutic use MeSH
- Cecum surgery MeSH
- Crohn Disease diagnostic imaging drug therapy surgery MeSH
- Child MeSH
- Gastroscopy MeSH
- Ileum surgery MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Infliximab therapeutic use MeSH
- Infant MeSH
- Colonoscopy MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Prospective Studies MeSH
- Recurrence MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Adalimumab MeSH
- Anti-Inflammatory Agents MeSH
- Azathioprine MeSH
- Immunosuppressive Agents MeSH
- Infliximab MeSH
OBJECTIVES: Intestinal surgery is an important part of Crohn disease (CD) treatment in children. The aim of the present study was to compare the rate of endoscopic recurrence at the sixth month after ileocecal resection (ICR) in children with CD treated with azathioprine between patients who received prior antitumor necrosis factor alpha (anti-TNF-α) therapy and those who were not administered this therapy. Moreover, we tried to identify the potential risk factors for disease recurrence and describe the schedule of long-term follow-up after surgery. METHODS: We prospectively collected data from pediatric patients with CD, who underwent ICR between October 2011 and June 2015 at our hospital and were treated with azathioprine monotherapy after ICR. We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients. RESULTS: Among 21 included patients, 13 achieved endoscopic remission (Rutgeerts score < i2) at the sixth month after ICR. No difference was found between patients who received prior anti-TNF-α therapy and those who did not. We did not find any clinically relevant factors associated with endoscopic recurrence rate at the sixth month. CONCLUSIONS: Prior anti-TNF-α therapy does not seem to be a strong risk factor for endoscopic recurrence within 6 months after ICR. Further studies on large sample of patients are needed to identify potential predictors of disease recurrence.
References provided by Crossref.org
Kono-S anastomosis in Crohn's disease: initial experience in pediatric patients